Hikma Beats GSK, Pfizer In Argatroban IP Infringement Row

Law360, New York (July 31, 2012, 7:17 PM EDT) -- GlaxoSmithKline PLC and Pfizer Inc. on Tuesday failed to stop Hikma Pharmaceutical Co. Ltd. from selling a generic version of anti-coagulant Argatroban after a New Jersey federal judge ruled the company hadn't infringed a patent associated with the drug.

U.S. District Judge Freda L. Wolfson granted Hikma's request for a declaration that the company didn't infringe a patent assigned to both GSK and Pfizer, while denying the companies' request for a judgment of infringement.

Judge Wolfson, however, also deflected Hikma's request for a declaration that the...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.